Virios Therapeutics, Inc. (NASDAQ: VIRI) had its price target raised by analysts at HC Wainwright from $0.20 to $5.00. They now have a "neutral" rating on the stock.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, NAPA, VIRI on Behalf of Shareholders
VIRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Virios Therapeutics, Inc. Is Fair to Shareholders
Virios, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics [Seeking Alpha]
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: "DWTX") [Financial Post (Toronto, Ontario, Canada)]